"After years of unexplained discomfort and inconclusive medical tests, a man’s self-driven online research led him to a rare diagnosis, highlighting the growing role of patient advocacy and social media in uncovering obscure medical conditions."
For decades, a significant portion of the population has grappled with a constellation of uncomfortable and often embarrassing symptoms, including a distended abdomen, persistent gurgling noises emanating from the throat, and excessive flatulence. These ailments, frequently misattributed to common digestive issues, have historically evaded definitive diagnosis, leaving individuals frustrated and without effective treatment. However, a recent case, detailed in the journal Cureus, offers a crucial glimpse into a condition that has only recently gained formal recognition: retrograde cricopharyngeus dysfunction, more commonly known as no-burp syndrome. This particular patient’s journey is noteworthy not only for the eventual identification of this rare disorder but also for the unusual circumstances surrounding its onset and the patient’s co-occurring diagnosis of Gilles de la Tourette syndrome.
No-burp syndrome, a condition characterized by an inability to voluntarily or involuntarily expel swallowed air from the upper gastrointestinal tract, results from the failure of the cricopharyngeus muscle – a crucial sphincter at the top of the esophagus – to relax appropriately. This anatomical dysfunction traps air, leading to the signature symptoms of bloating, audible gastric sounds, chest discomfort, and uncontrollable gas. While descriptions of individuals unable to burp date back to the late 1980s, it wasn’t until 2019 that the condition was formally identified and named by laryngologist Robert Bastian and physician assistant Melissa Smithson. Their groundbreaking work involved treating 51 patients with botulinum toxin injections into the cricopharyngeus muscle, resulting in the restoration of their ability to burp and significant relief from their debilitating symptoms. Remarkably, the positive effects of these injections often outlasted the typical duration of the toxin’s action.
Subsequent research has further solidified the efficacy of this treatment. A 2020 follow-up study from Bastian’s practice, analyzing their first 200 treated patients, reported a staggering 99.5% success rate in regaining the ability to burp. This finding underscores the significant unmet need that R-CPD represents, as many patients endure years of consultations with multiple physicians and undergo various diagnostic procedures before arriving at the correct diagnosis. Standard medical tests often fail to detect the subtle functional anomaly of the cricopharyngeus muscle, contributing to diagnostic delays. A comprehensive review published in 2024 by Johns Hopkins acknowledged that symptoms typically manifest in adolescence, with patients frequently embarking on lengthy diagnostic odysseys that can span years.
The patient in the Cureus report presents an atypical profile that challenges prevailing understandings of R-CPD’s typical presentation. Most individuals diagnosed with no-burp syndrome report a lifelong inability to burp, suggesting a congenital predisposition. In stark contrast, this 30-something man’s symptoms emerged following a period of transient dysphagia, or difficulty swallowing. This acquired nature of his R-CPD distinguishes him as an outlier among reported cases. Research published in 2026 in the journal Toxins, analyzing data across multiple studies, found that approximately 55% of patients with R-CPD had a history of the condition from childhood, with the remaining cases typically beginning in adolescence and rarely in adulthood. Furthermore, a social media survey of 199 patients indicated that about 22% had a family history of the disorder, suggesting a potential genetic component in some individuals.
Adding another layer of complexity to his case is the co-occurrence of Gilles de la Tourette syndrome, a neurological disorder characterized by involuntary, repetitive movements and vocalizations known as tics. While the case report does not establish a causal link between Tourette syndrome and R-CPD, the authors acknowledge the challenges that a concurrent diagnosis can pose for patient care and diagnosis. It is important to note that this single case report cannot definitively determine whether individuals with Tourette syndrome face an elevated risk of developing R-CPD. The patient in question received a botulinum toxin injection into his cricopharyngeus muscle, which initially yielded positive results. The authors of the study advocate for increased clinician awareness of R-CPD in patients presenting with similar constellations of symptoms.
The patient’s diagnostic pathway is increasingly mirroring a growing trend, largely driven by the burgeoning influence of social media platforms. The Johns Hopkins review highlights a significant rise in R-CPD presentations directly attributable to patient-led online communities. These platforms have become invaluable resources where individuals share their experiences, symptoms, and potential diagnoses, often self-diagnosing before consulting healthcare professionals. This phenomenon is not surprising, given the documented struggles patients face within the traditional healthcare system. An interview-based study published in Neurogastroenterology & Motility revealed that only half of the 199 adults with R-CPD had discussed their symptoms with a primary care physician, and a staggering 90% felt they did not receive adequate medical attention. Participants frequently reported experiencing embarrassment, anxiety, depression, strained interpersonal relationships, and significant disruptions to their professional lives. The pervasive symptoms of bloating, socially awkward gurgling, excessive flatulence, and even difficulty vomiting significantly impact their quality of life.
Botulinum toxin injection remains the primary therapeutic intervention for R-CPD. However, the field still faces challenges, including the absence of a standardized dosing protocol and variability in the duration of relief. Some patients require repeat injections, while a small subset may eventually opt for surgical intervention to partially sever the cricopharyngeus muscle. Potential side effects, though rare, have been documented. A 2026 report from the University of Southern California described a 41-year-old man who, after receiving two botulinum toxin injections, regained his ability to burp but subsequently developed dysphagia. Diagnostic testing revealed transiently weakened muscle contractions in his pharynx and upper esophagus, with no underlying neuromuscular disease identified.
The Cureus report currently details only the initial benefit observed in the patient. Long-term outcomes, including the duration of relief and any potential influence of his Tourette syndrome on the efficacy of the treatment, remain to be seen. For individuals who have never been able to burp, or who have lost this ability and subsequently experience symptoms such as gurgling, bloating, and excessive gas, inquiring about R-CPD with a healthcare professional is advisable, particularly if conventional treatments for other gastrointestinal disorders have proven ineffective. An ear, nose, and throat specialist with expertise in swallowing disorders is well-equipped to evaluate these symptoms. Crucially, any new onset of swallowing difficulties warrants prompt medical attention, as this symptom can be indicative of a wide range of underlying medical conditions.
Key Questions Answered
What is no-burp syndrome?
Retrograde cricopharyngeus dysfunction, or R-CPD, is a condition where the cricopharyngeus muscle, a ring of muscle at the top of the esophagus, fails to relax, preventing the expulsion of swallowed air. This leads to symptoms such as bloating, gurgling sounds, chest pressure, and excessive flatulence.
What made this case unusual?
This particular case is notable because the patient, a man in his 30s, was diagnosed with R-CPD after a period of temporary difficulty swallowing, rather than having the condition from childhood, which is the more typical presentation. Additionally, he has a co-occurring diagnosis of Gilles de la Tourette syndrome, although no direct link between the two conditions has been established.
How was he diagnosed?
After enduring years of persistent, unexplained symptoms and undergoing numerous inconclusive medical tests, the patient independently researched his symptoms online. He identified a condition that matched his experience and subsequently proposed R-CPD to his ear, nose, and throat specialist, leading to his diagnosis.
How is R-CPD treated?
The primary treatment for R-CPD is an injection of botulinum toxin into the cricopharyngeus muscle. This procedure aims to relax the muscle, allowing air to escape and relieving symptoms. The patient in the reported case experienced an initial positive response to this treatment.
Does Tourette syndrome cause R-CPD?
Currently, there is no established scientific link between Tourette syndrome and retrograde cricopharyngeus dysfunction. The case report does not suggest that Tourette syndrome causes R-CPD; rather, it highlights the presence of both conditions in the same individual and the potential complexities this may introduce in patient care. Further research would be needed to explore any potential correlations.
